---
schema_version: "secwatch.filing_event.v1"
accession: "0001819790-25-000100"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:20:57.944223+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Tarsus annual meeting: directors elected, say-on-pay approved, Ernst & Young ratified

## Summary
- Stockholders elected Bobak Azamian, M.D., Ph.D. (20.8M for) and Katherine Goodrich, M.D. (26.8M for) as Class II directors.
- Non-binding advisory vote approved named executive officer compensation: 27.1M for, 416,845 against, 16,635 abstain.
- Stockholders selected an every-1-year frequency for future say-on-pay votes (26.9M votes for 1 year).
- Ratification of Ernst & Young LLP as independent auditor for FY2025 approved: 34.7M for, 125,755 against, 7,803 abstain.

## SEC filing metadata
- accession: 0001819790-25-000100
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/0001819790-25-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000181979025000100/tars-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001819790-25-000100
- JSON: https://secwatch.observer/filing/0001819790-25-000100.json
- Plain text: https://secwatch.observer/filing/0001819790-25-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.